- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
China Resources Pharmaceutical Group
Market Cap: HK$30.7b
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally.
3320
HK$4.89
7D
-2.2%
1Y
-1.8%
Essex Bio-Technology
Market Cap: HK$3.0b
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.
1061
HK$5.27
7D
-4.9%
1Y
133.2%